The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
about
DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome projectHistone deacetylases (HDACs): characterization of the classical HDAC familyThe histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.A phase 2 study of vorinostat in acute myeloid leukemiaRegulation of the Telomerase Reverse Transcriptase Subunit through Epigenetic MechanismsGlobal histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARĪ³Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylasesQuantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass SpectrometryActivation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiationLaboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphomaEpigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomasEffects of Trichostatin A on In vitro Development of Porcine Embryos Derived from Somatic Cell Nuclear TransferDifferential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions.Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase.Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study.MYB suppresses differentiation and apoptosis of human breast cancer cells.Tackling the cancer stem cells - what challenges do they pose?The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone lossInterpreting clinical assays for histone deacetylase inhibitors.pp32 reduction induces differentiation of TSU-Pr1 cells.Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaExpression of histone deacetylases 1, 2 and 3 in urothelial bladder cancerTBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cellsSuberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell lineThe crossroads between cancer stem cells and aging.Targeting Histone Deacetylases in Diseases: Where Are We?Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1Solid tumor differentiation therapy - is it possible?Fresh Garlic Extract Induces Growth Arrest and Morphological Differentiation of MCF7 Breast Cancer CellsInhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.Epigenetic Therapy in Breast Cancer.Epigenetics as a therapeutic target in breast cancer.Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 CellsNoninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenograftsA phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium studySustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma CellsEpigenetic targeting in breast cancer: therapeutic impact and future direction.
P2860
Q21146392-6B5B40CD-5F00-40AB-AB14-E4EEBE10A890Q24535587-F9F9629E-C4A9-413C-BA72-84ABCDEC5516Q24535620-E7FAE8FC-1C73-4B44-A235-59A60A94C111Q24643266-D321CD5F-6529-4E53-A78A-686FE1D15CD4Q26744572-27281005-B70B-4131-95D2-C376F4FF1B8AQ26775413-80DD75EF-337D-423F-8007-A72FA212427BQ28541836-20014CEC-5A7C-46EA-A18C-CC6683C3B12EQ28585055-D9E3311B-A5BE-44DB-988A-CC5E83C1E79EQ30977451-3D760597-6912-4775-90E5-538DAD6FDAA1Q33634245-B263889F-ACD3-49E0-BCF6-AB6F0F02FBF7Q33726989-D815759C-F632-4C48-BA2A-AA0434A3D388Q33742171-8D2B1330-AC88-40FF-9474-B37BE8A898EDQ33883997-8E4FB713-D01A-4BBF-86D4-9EB4E0A86628Q33943916-BE95AD03-3356-4473-9611-29740FCD52CDQ33966855-D76E2B27-F335-4227-8C5D-EF674D276BEDQ34025851-0A98581D-C9D4-44D6-9EAB-B0E47C6332C2Q34059184-45815C01-1CC8-48D7-8D60-8B116CF0100DQ34173485-52302F52-36E4-42A7-A10C-6DC40EFF19AFQ34523263-C6763686-738F-453A-922D-69235C522DD1Q34686787-70E89F40-A13D-487C-80EF-4CC3F27C8BB5Q35003657-898F7D6B-946A-4D51-8176-15241F29BACEQ35083306-2761BD82-9F20-46CF-87F2-91FD1E3344A0Q35096240-2C66017D-B443-41E1-8809-0C4B2AAF7E0AQ35119480-25B7548D-647B-4331-AFA6-989F0529F346Q35155635-10C52433-44E8-4442-A75E-FB3285E47DACQ35218534-1FA984EC-5B4A-4A6A-98FE-70F7D801C3FAQ35232590-040FD90A-71B2-4620-921D-A7B5D5789070Q35566484-E1F09A7E-E7C4-445F-8BD2-8BB3C7A2487BQ35821728-083BBE98-7110-48E1-B14B-F02C092797A0Q36017473-7EEC4156-72AA-4E3F-8B14-B9ABED588EABQ36071880-D41FC5DA-41E1-4100-8D6B-93280DD75A46Q36296478-457FAD63-7D7F-4F63-9B2A-7167752354AAQ36302249-122923DF-5D9B-4660-AD00-DD4104CC2076Q36337694-7836214D-6A66-4FB4-A565-1D83C367F2ABQ36449057-96E0AFE7-7909-4C7A-9293-4FC6D2F68E76Q36517161-6071644B-8497-4698-ADC3-288D56ECD287Q36528232-19D12EED-FC9E-4B9A-9F7E-DF9FD26EEA43Q36528653-500E3DF5-4E01-48FF-889F-365B4B72E114Q36702019-6DBCAD9A-71A1-41F7-806E-780041AA8A16Q36856318-FE4D487A-C0AE-445F-8797-31A7383FF441
P2860
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
description
2001 nĆ® lÅ«n-bĆ»n
@nan
2001幓ć®č«ę
@ja
2001幓å¦ęÆęē«
@wuu
2001幓å¦ęÆęē«
@zh-cn
2001幓å¦ęÆęē«
@zh-hans
2001幓å¦ęÆęē«
@zh-my
2001幓å¦ęÆęē«
@zh-sg
2001幓åøč”ęē«
@yue
2001幓åøč”ęē«
@zh
2001幓åøč”ęē«
@zh-hant
name
The histone deacetylase inhibi ...... of human breast cancer cells.
@en
type
label
The histone deacetylase inhibi ...... of human breast cancer cells.
@en
prefLabel
The histone deacetylase inhibi ...... of human breast cancer cells.
@en
P2093
P1433
P1476
The histone deacetylase inhibi ...... of human breast cancer cells.
@en
P2093
Munster PN
Troso-Sandoval T
P304
P407
P577
2001-12-01T00:00:00Z